- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT01134666
An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer
연구 개요
상세 설명
Cetuximab, a chimeric immunoglobulin G1 (IgG1) monoclonal antibody, has been found to potentiate the effects of chemotherapy and radiotherapy in experimental systems. The findings from clinical trials suggest a favorable risk-benefit ratio of the combination of irinotecan or oxaliplatin, infusional 5-FU/FA and biweekly cetuximab, and support the current study to demonstrate the therapeutic value of the biweekly cetuximab regimen as a combination partner for those regimens in subjects with KRAS wild-type mCRC in the first-line setting. The purpose of this study is to generate post marketing surveillance (PMS) data for cetuximab in first-line mCRC, which is mandated by the Licensing Authorities.
This is an open-label, non-randomized, prospective, multicentric Phase IV study evaluating FOLFIRI/ FOLFOX plus cetuximab in the first-line therapy of subjects with KRAS wild-type metastatic CRC. The study plans to enroll 100 subjects with KRAS wild type CRC at 20 centres across India. Tumour status, physical and laboratory examinations will be performed during the baseline visit. Subjects will be administered FOLFIRI/ FOLFOX and cetuximab according to the clinical condition in the following treatment visits. Regular safety assessments and all adverse events (AEs) will be documented throughout and until the end-of-study visit. The outcome of AEs ongoing at the final tumour assessment visit will be followed up at the end-of-study visit (If possible, 6 weeks after the last administration of study medication but before second-line anticancer treatment, and not earlier than 30 days after the end of study treatment). Skin toxicity present at the end-of-study visit will be followed up until outcome is known.
OBJECTIVES
Primary Objective:
- To evaluate the safety and tolerability of Cetuximab in combination with standard chemotherapy such as FOLFOX or FOLFIRI as first-line therapy of patients with KRAS wild-type metastatic colorectal cancer.
Secondary Objective:
- To evaluate the efficacy of Cetuximab in combination with standard chemotherapy as first-line therapy of patients with KRAS wild-type metastatic colorectal cancer.
연구 유형
등록 (실제)
연락처 및 위치
연구 장소
-
-
-
Delhi, 인도, 110055
- Nothern Railway Central Hospital
-
Delhi, 인도, 110076
- Indraprastha Apollo Hospital
-
Delhi, 인도, 110092
- Shanti Mukand Hospital
-
Delhi, 인도, 110096
- Dharamshila Cancer Hospital & Research Centre
-
-
Andhra Pradesh
-
Hyderabad, Andhra Pradesh, 인도, 500034
- Indo- American Cancer Institute & Research Centre
-
Hyderabad, Andhra Pradesh, 인도, 500063
- NVS Ramakrishna's Clinic
-
Secunderabad, Andhra Pradesh, 인도, 500025
- Dr. Nikhil's Clinic
-
Secunderabad, Andhra Pradesh, 인도, 500025
- Nikhil Gharyalpatil's Clinic
-
-
Andrapradesh
-
Hyderabad, Andrapradesh, 인도, 500001
- Ravi Kumar's Clinic
-
Hyderabad, Andrapradesh, 인도, 500008
- Ambaa Hospitals
-
Hyderabad, Andrapradesh, 인도, 500059
- Swarna Sai Hospital
-
-
Bangalore
-
Mangalore, Bangalore, 인도, 575 001
- Manipal Centre For Clinical Research
-
-
Calicut
-
Kerala, Calicut, 인도, 673016
- Medical College Calicut
-
-
Gujarat
-
Ahmedabad, Gujarat, 인도, 380009
- Hemato Oncology Clinic
-
-
Karnataka
-
Hubli, Karnataka, 인도, 580020
- Kattimani Oncology Clinic
-
-
Kashmir
-
Srinagar, Kashmir, 인도, 190001
- SKIMS
-
Srinagar, Kashmir, 인도, 190010
- S. K. I. M. S.
-
-
Madhya Pradesh
-
Bhopal, Madhya Pradesh, 인도, 462001
- Dr. T. P. Sahoo's Clinic
-
-
Maharashtra
-
Mumbai, Maharashtra, 인도, 400014
- BND Onco Centre
-
Mumbai, Maharashtra, 인도, 400071
- Joy Hospital
-
Pune, Maharashtra, 인도, 411001
- Ruby Hall Clinic
-
-
Mizoram
-
Aizwal, Mizoram, 인도, 796 009
- Grace Nursing Home
-
-
Mumbai
-
Bandra, Mumbai, 인도, 400050
- Lilavati Hospital
-
Mahim, Mumbai, 인도, 400016
- S.L.Raheja Hospital
-
-
New Delhi
-
Delhi, New Delhi, 인도, 110044
- Apollo Cancer Institute
-
Delhi, New Delhi, 인도, 110085
- Rajiv Gandhi Cancer Institute & Research
-
-
Punjab
-
Amritsar, Punjab, 인도, 143004
- Fortis Escorts Hospital
-
Chandigarh, Punjab, 인도, 160101
- Dr. Rajeev Bedi's Clinic
-
Ludhiana, Punjab, 인도, 141001
- D.M.C Hospital
-
Mohali, Punjab, 인도, 160071
- IVY Hospital
-
-
Rajasthan
-
Jaipur, Rajasthan, 인도, 302004
- SMS Hospital
-
Jaipur, Rajasthan, 인도, 302004
- Cancer Clinic
-
Jaipur, Rajasthan, 인도, 302006
- Bhagwan Mahaveer Cancer Hospital
-
Jaipur, Rajasthan, 인도, 302030
- Bhagwan Mahaveer Cancer Hospital & Research Centre
-
Jodhpur, Rajasthan, 인도, 3420003
- Vyas Cancer Care
-
-
Tamilnadu
-
Trivandrum, Tamilnadu, 인도, 695011
- TC 14/ 764 Sreemangalam
-
-
Uttar Pradesh
-
Ghaziabad, Uttar Pradesh, 인도, 201014
- Shati Gopal Hospital
-
Lucknow, Uttar Pradesh, 인도, 226007
- Annapurna Medical and Cancer Relief Society
-
-
West Bengal
-
Kolkata, West Bengal, 인도, 700026
- Chittaranjan National Cancer Institute
-
Kolkata, West Bengal, 인도, 700054
- Apollo Gleneagles Cancer Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 어린이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- Subjects with histologically confirmed, adenocarcinoma of the colon or rectum (mCRC)
- Subjects with KRAS wild-type status of tumour tissue
- Chemotherapy naïve subjects
- Subject who have signed written informed consent (as per institutional protocol)
Exclusion Criteria:
- As per summary of product characteristics of cetuximab
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
---|---|
Safety and tolerability evaluated based on the incidence and severity of AEs.
기간: From baseline to follow-up visit for any ongoing AEs
|
From baseline to follow-up visit for any ongoing AEs
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Response rate
기간: Baseline to End-of-Study Visit
|
Disease Control Rate (DCR), Progression Free Survival (PFS)and Overall Survival (OS)
|
Baseline to End-of-Study Visit
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Rajiv Rana, MD, Merck Ltd., India
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
Cetuximab에 대한 임상 시험
-
Cancer Institute and Hospital, Chinese Academy...모병
-
Spanish Cooperative Group for the Treatment of...완전한
-
Universitaire Ziekenhuizen KU LeuvenMerck KGaA, Darmstadt, Germany완전한
-
Assistance Publique - Hôpitaux de ParisGERCOR - Multidisciplinary Oncology Cooperative Group완전한
-
University Medical Center Groningen모병
-
St. Luke's-Roosevelt Hospital CenterBristol-Myers Squibb종료됨
-
Gustave Roussy, Cancer Campus, Grand ParisMinistry of Health, France완전한